Neutralny
Pfizer's stock remains near 52-week low at $24.25, offering 7.1% dividend yield.
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
Pfizer's stock price has stabilized around $24.25, close to its 52-week low, providing investors with a 7.1% dividend yield. This stability comes amid strategic shifts, including the $43 billion Seagen oncology acquisition aimed at doubling cancer revenue by 2030. However, the company faces challenges such as the loss of exclusivity for its top-selling drug, Eliquis, in Europe, which could impact future revenue.
Kluczowe punkty
- Pfizer's stock trades at $24.25, near its 52-week low, offering a 7.1% dividend yield.
- The $43 billion Seagen oncology acquisition aims to double cancer revenue by 2030.
- Eliquis lost European exclusivity in May, potentially affecting $6-7 billion in revenue.
Źródła
- Pfizer Stock Forecast — PFE ($24.25) Pays a 7.1% Yield Near Its Low as Seagen Races the Eliquis Cliff — Value or Trap?TradingNews · July 10, 2026
- Pfizer Could Rewrite the GLP-1 Race — but Its 7% Yield Is Flashing a WarningNAI 500 · July 10, 2026
- Pfizer Stock Price Forecast - PFE Shares Rebounds to $24.51 as Seagen and Metsera Deals Reshape 2025 OutlookTradingNews · October 18, 2025
- La FDA aprueba la píldora Veppanu de Pfizer-Arvinas para cáncer de mamaInvesting.com · May 2, 2026
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
